Current Report Filing (8-k)
May 08 2019 - 5:03PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 8, 2019
HARVARD
BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
001-33957
|
04-3306140
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
84 October Hill Road, Holliston, MA
|
01746
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant's telephone number, including
area code:
(508) 893-8999
________________________________________________________________________________
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
[ ]
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
[ ]
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
[ ]
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
[ ]
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.01 par value
|
HBIO
|
The NASDAQ Stock Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
|
Departure of Chief Financial Officer
On May 8, 2019, Kamalam Unninayar submitted
her resignation from all positions held with Harvard Bioscience, Inc. (the “Company”), including her position as Chief
Financial Officer (“CFO”), such resignation to be effective as of May 31, 2019. Ms. Unninayar did not resign for any
reasons related to the Company’s accounting practices or financial statements. The Company has initiated a search for Ms.
Unninayar’s successor as CFO.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
Harvard
BIOSCIENCE, INC.
(Registrant)
|
May 8, 2019
(Date)
|
|
/s/ JEFFREY A. DUCHEMIN
Jeffrey A. Duchemin
Chief Executive Officer
|
Harvard Bioscience (NASDAQ:HBIO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Harvard Bioscience (NASDAQ:HBIO)
Historical Stock Chart
From Oct 2023 to Oct 2024